LTK 融合：非小细胞肺癌的新靶点出现。
LTK fusions: A new target emerges in non-small cell lung cancer.
机构信息
Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Pfizer Worldwide Research and Development, La Jolla, CA, USA.
出版信息
Cancer Cell. 2022 Jan 10;40(1):23-25. doi: 10.1016/j.ccell.2021.12.012.
Abstract
Identification of targetable fusions as oncogenic drivers in non-small cell lung cancer has transformed its diagnostic and therapeutic paradigm. In a recent article in Nature, Izumi et al. report the discovery of CLIP1-LTK fusion as a novel oncogenic driver in lung cancer, targetable using the ALK tyrosine kinase inhibitor lorlatinib.
摘要
鉴定非小细胞肺癌中的可靶向融合作为致癌驱动因子已经改变了其诊断和治疗模式。在最近发表在《自然》杂志上的一篇文章中，Izumi 等人报道了 CLIP1-LTK 融合作为肺癌中新的致癌驱动因子的发现，该融合可以使用 ALK 酪氨酸激酶抑制剂 lorlatinib 进行靶向治疗。
相似文献
1
LTK fusions: A new target emerges in non-small cell lung cancer.LTK 融合：非小细胞肺癌的新靶点出现。
Cancer Cell. 2022 Jan 10;40(1):23-25. doi: 10.1016/j.ccell.2021.12.012.
2
The - fusion: a new oncogenic driver in non-small-cell lung cancer?-融合：非小细胞肺癌中的一种新的致癌驱动因素？
Future Oncol. 2023 Feb;19(4):273-275. doi: 10.2217/fon-2022-1232. Epub 2023 Mar 21.
3
LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.LTK 突变导致携带 CLIP1-LTK 融合的非小细胞肺癌对 lorlatinib 耐药。
Commun Biol. 2024 Apr 4;7(1):412. doi: 10.1038/s42003-024-06116-6.
4
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.CLIP1-LTK 融合是一种非小细胞肺癌的致癌驱动基因。
Nature. 2021 Dec;600(7888):319-323. doi: 10.1038/s41586-021-04135-5. Epub 2021 Nov 24.
5
Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer.肺癌中涉及酪氨酸激酶受体的可操作基因融合和扩增的生物学和临床观点。
Cancer Treat Rev. 2022 Sep;109:102430. doi: 10.1016/j.ctrv.2022.102430. Epub 2022 Jun 18.
6
[Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer].[间变性淋巴瘤激酶在非小细胞肺癌中的现状]
Zhongguo Fei Ai Za Zhi. 2018 Sep 20;21(9):703-711. doi: 10.3779/j.issn.1009-3419.2018.09.10.
7
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.受体酪氨酸激酶融合作为表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）在EGFR突变的非小细胞肺癌中可利用的耐药机制
Trends Cancer. 2019 Nov;5(11):677-692. doi: 10.1016/j.trecan.2019.09.008. Epub 2019 Oct 29.
8
miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.miR-100-5p 赋予 EML4-ALK 阳性 NSCLC 对 ALK 酪氨酸激酶抑制剂克唑替尼和洛拉替尼的耐药性。
Biochem Biophys Res Commun. 2019 Apr 2;511(2):260-265. doi: 10.1016/j.bbrc.2019.02.016. Epub 2019 Feb 18.
9
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。
Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.
10
ALK inhibitors in the treatment of advanced NSCLC.ALK 抑制剂治疗晚期 NSCLC。
Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7.
引用本文的文献
1
Inhibition of RPA32 and Cytotoxic Effects of the Carnivorous Plant Root Extract in Non-Small-Cell Lung Cancer Cells.食肉植物根提取物对非小细胞肺癌细胞中RPA32的抑制作用及细胞毒性效应。
Plants (Basel). 2025 May 9;14(10):1426. doi: 10.3390/plants14101426.
2
Fuel for thought: targeting metabolism in lung cancer.值得思考的问题：以肺癌中的代谢为靶点
Transl Lung Cancer Res. 2024 Dec 31;13(12):3692-3717. doi: 10.21037/tlcr-24-662. Epub 2024 Dec 24.
3
A comprehensive meta-analysis of tissue resident memory T cells and their roles in shaping immune microenvironment and patient prognosis in non-small cell lung cancer.全面的组织驻留记忆 T 细胞荟萃分析及其在塑造非小细胞肺癌免疫微环境和患者预后中的作用。
Front Immunol. 2024 Jul 8;15:1416751. doi: 10.3389/fimmu.2024.1416751. eCollection 2024.
4
Lung cancer in patients who have never smoked - an emerging disease.从不吸烟患者的肺癌——一种新出现的疾病。
Nat Rev Clin Oncol. 2024 Feb;21(2):121-146. doi: 10.1038/s41571-023-00844-0. Epub 2024 Jan 9.
5
Renal pelvis sarcomatoid carcinoma with renal vein tumor thrombus: A case report and literature review.肾盂肉瘤样癌伴肾静脉瘤栓：一例报告及文献复习
World J Clin Cases. 2023 Nov 6;11(31):7690-7698. doi: 10.12998/wjcc.v11.i31.7690.
6
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.PI3K/AKT/mTOR 信号转导通路与癌症的靶向治疗。
Mol Cancer. 2023 Aug 18;22(1):138. doi: 10.1186/s12943-023-01827-6.
7
Tyrosine Kinase Inhibitors Target B Lymphocytes.酪氨酸激酶抑制剂靶向 B 淋巴细胞。
Biomolecules. 2023 Feb 25;13(3):438. doi: 10.3390/biom13030438.
8
Recent progress in targeted therapy for non-small cell lung cancer.非小细胞肺癌靶向治疗的最新进展
Front Pharmacol. 2023 Feb 21;14:1125547. doi: 10.3389/fphar.2023.1125547. eCollection 2023.
本文引用的文献
1
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.CLIP1-LTK 融合是一种非小细胞肺癌的致癌驱动基因。
Nature. 2021 Dec;600(7888):319-323. doi: 10.1038/s41586-021-04135-5. Epub 2021 Nov 24.
2
Lung cancer.肺癌。
Lancet. 2021 Aug 7;398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3. Epub 2021 Jul 21.
3
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.非小细胞肺癌中的致癌驱动基因突变：过去、现在与未来
World J Clin Oncol. 2021 Apr 24;12(4):217-237. doi: 10.5306/wjco.v12.i4.217.
4
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.高产量 RNA 测序在 DNA 测序未检测到有丝分裂驱动改变且肿瘤突变负担低的肺腺癌中发现可靶向的激酶融合。
Clin Cancer Res. 2019 Aug 1;25(15):4712-4722. doi: 10.1158/1078-0432.CCR-19-0225. Epub 2019 Apr 26.
5
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in -Positive Non-Small-Cell Lung Cancer.ALK阳性非小细胞肺癌的转移扩散模式及对克唑替尼的耐药机制
JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.
6
Targeting ALK: Precision Medicine Takes on Drug Resistance.靶向ALK：精准医学应对耐药性。
Cancer Discov. 2017 Feb;7(2):137-155. doi: 10.1158/2159-8290.CD-16-1123. Epub 2017 Jan 25.
7
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.（10R）-7-氨基-12-氟-2,10,16-三甲基-15-氧代-10,15,16,17-四氢-2H-8,4-（亚甲二氧基）吡唑并[4,3-h][2,5,11]-苯并恶二嗪环十四烷-3-甲腈（PF-06463922）的发现，这是一种间变性淋巴瘤激酶（ALK）和 c-ros 原癌基因 1（ROS1）的大环抑制剂，具有临床前脑暴露和广谱活性，可对抗 ALK 耐药突变。
J Med Chem. 2014 Jun 12;57(11):4720-44. doi: 10.1021/jm500261q. Epub 2014 Jun 3.
8
ALK-activating homologous mutations in LTK induce cellular transformation.LTK 中的 ALK 激活同源突变诱导细胞转化。
PLoS One. 2012;7(2):e31733. doi: 10.1371/journal.pone.0031733. Epub 2012 Feb 9.
9
Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer.非小细胞肺癌中转移相关受体酪氨酸激酶的鉴定
Cancer Res. 2005 Mar 1;65(5):1778-82. doi: 10.1158/0008-5472.CAN-04-3388.
10
Leukocytes express a novel gene encoding a putative transmembrane protein-kinase devoid of an extracellular domain.白细胞表达一种编码假定跨膜蛋白激酶的新基因，该激酶缺乏细胞外结构域。
Nature. 1988 Jun 16;333(6174):672-6. doi: 10.1038/333672a0.
Zotero 插件